Evidence map›Paper›PMID 39495264›Full record

SynthesisNaunyn-Schmiedeberg's archives of pharmacology2025

Sarecycline for moderate to severe acne: a promising narrow-spectrum antibacterial drug.

Amr Elrosasy, Mohamed Abo Zeid, Esraa M AlEdani, Amira A Aboali, Aya M Fayoud, Kareem Ibraheem, Maha Abdullah Alwaili, Samy Selim, Ahmed Hamdy Zabady

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amr ElrosasyFaculty of Medicine, Cairo University, Cairo, Egypt.
Mohamed Abo ZeidFaculty of Medicine, Tanta University, Tanta, Egypt. Mohamed_31059599@med.tanta.edu.eg.ORCID 0009-0007-8165-9470
Esraa M AlEdaniBasra Medical College, Basra, Iraq.
Amira A AboaliFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Aya M FayoudFaculty of Pharmacy, Kafr El Shiekh University, Kafr El Shiekh, Egypt.
Kareem IbraheemFaculty of Medicine, Palestine Polytechnic University, Hebron, Palestine.
Maha Abdullah AlwailiDepartment of Biology, College of Science, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, 11671, Riyadh, Saudi Arabia.
Samy SelimDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, 72388, Sakaka, Saudi Arabia.
Ahmed Hamdy ZabadyFaculty of Science, Damanhour University, Damanhour, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarecycline, a narrow-spectrum antibacterial drug approved by the FDA in 2018, targets Cutibacterium acnes while potentially minimizing disruption to the gut microbiota. The aim of this study is to assess the efficacy and safety of sarecycline compared to placebo in treating moderate to severe facial acne. A comprehensive search of PubMed, MEDLINE, and Cochrane databases was performed, with data extraction and screening conducted independently by two authors. Statistical analysis used RevMan, and the risk of bias was evaluated using RoB 2. Three RCTs (n = 2287 patients, mean age 19.6-20.8 years) met the inclusion criteria. Sarecycline (1.5 mg/kg) administered daily for 12 weeks significantly reduced inflammatory and non-inflammatory lesion counts compared to placebo (p < 0.00001). Other outcomes were not statistically significant. Sarecycline 1.5 mg/kg daily is an effective and well-tolerated treatment for moderate to severe acne with minimal side effects.

Indexed as

Acne VulgarisAnti-Bacterial AgentsTetracyclinesHumansPropionibacterium acnesRandomized Controlled Trials as TopicSeverity of Illness IndexTreatment OutcomeYoung AdultAnti-Bacterial AgentssarecyclineTetracyclinesAcne vulgarisInflammatory lesionsPapulesPustulesSarecycline

Identifiers

PMID39495264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.